American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Systematic Review and Network Meta-Analysis of the Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-Refractory Multiple Myeloma

ASH 2020 – Multiple Myeloma

Results from a network meta-analysis demonstrated that triple therapy is superior to dual therapy for lenalidomide-refractory patients with multiple myeloma, with the highest efficacy achieved with triple therapy that included a monoclonal antibody. Read More ›

ANCHOR: Melflufen + Dexamethasone and Daratumumab or Bortezomib in RRMM Patients Refractory to an IMiD and/or Proteasome Inhibitor

ASH 2020 – Multiple Myeloma

The analysis of updated efficacy and safety data from the ANCHOR study of melphalan flufenamide (melflufen) + dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging treatment efficacy that was well tolerated. Read More ›

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with RRMM

ASH 2020 – Multiple Myeloma

This updated analysis of a phase 1, first-in-human study of REGN5458 in heavily pretreated patients with RRMM is consistent with previous findings, showing an acceptable safety profile and deep and durable responses. Read More ›

Novel Therapeutic Strategies with P-BCMA-101 CAR T-Cells in Patients with RRMM: Phase 1/2 Study Results

ASH 2020 – Multiple Myeloma

This phase 1/2 study demonstrated favorable efficacy and low rates of toxicity with low doses of P-BCMA-101 CAR T-cells in patients with RRMM. The favorable safety profile prompted a protocol amendment to allow fully outpatient administration. Read More ›

Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, for RRMM

ASH 2020 – Multiple Myeloma

Results from a phase 1 study of talquetamab, a first-in-class bispecific antibody, show encouraging clinical activity with manageable toxicity in heavily pretreated patients with RRMM. The study is ongoing to identify a dose for phase 2 investigation. Read More ›

Teclistamab, a BCMA x CD3 Bispecific Antibody, in Patients with RRMM: Phase 1 Study Updates

ASH 2020 – Multiple Myeloma

The updated analysis of the phase 1 study of teclistamab in patients with RRMM shows favorable efficacy and manageable safety, and supports the planned phase 2 monotherapy trial at 1500 μg/kg administered subcutaneously. Read More ›

Depth of Response of Isatuximab + Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Interim Analysis

ASH 2020 – Multiple Myeloma

The IKEMA study interim analysis showed isatuximab + carfilzomib and dexamethasone resulted in a clinically meaningful improvement in depth of response, with more patients reaching minimal residual disease–negativity compared with carfilzomib and dexamethasone alone. Read More ›

Efficacy and Safety Results Following 12 Months of Maintenance Therapy with Lenalidomide or Daratumumab plus Lenalidomide

ASH 2020 – Multiple Myeloma

Updated efficacy and safety results of the phase 2 GRIFFIN study (NCT02874742) in patients with transplant-eligible, newly diagnosed multiple myeloma who received daratumumab plus lenalidomide, bortezomib, and dexamethasone. Read More ›

Circularly Permuted TRAIL, a Novel TRAIL Agonist, with Thalidomide and Dexamethasone in Patients with RRMM

ASH 2020 – Multiple Myeloma

Results from a phase 3 study of circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) + thalidomide and dexamethasone demonstrated this was a safe and effective treatment for patients with RRMM, including those with a poor prognosis. Read More ›

Phase 1 Results Presented for Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, for RRMM

ASH 2020 – Multiple Myeloma

Talquetamab, a first-in-class bispecific antibody, showed encouraging efficacy with manageable toxicity in heavily pretreated patients with RRMM. An ongoing phase 2 investigation will determine the optimal dosing. Read More ›

American Society of Hematology (ASH)

Page 12 of 44